Nigel Key, M.D., Director of the UNC Hemophilia and Thrombosis Center, is extensively quoted in the January 12, 2016 WebMD article “Hemophilia: New Treatments for an Old Disease,” by Sonya Collins.<\/p>\n
Although it\u2019s been nearly a century since hemophilia<\/span> was considered an early death sentence, treating it can be time-consuming and troublesome. Many people with the blood disease give themselves frequent drug infusions to keep their condition under control, sometimes as often as several times a week.<\/p>\n Several newly approved medications, while far from a cure, aim to lift some of that burden. Some will allow patients to go longer between treatments. Another drug in development aims to overcome a problem with current treatments, which can sometimes stop working for people whose bodies become resistant to them.<\/p>\n \u201cThere\u2019s never been a time when the pipeline is as full as it is now,\u201d says Nigel Key, MB, ChB, a hematologist and director of the Hemophilia and Thrombosis Center at the University of North Carolina. \u201cI think it\u2019s a reflection of the ability of biotechnology to bring these things forward.\u201d<\/p>\n